Preeclampsia affects up to 8% of pregnancies worldwide and remains a leading cause of maternal and fetal mortality, particularly when it develops before 34 weeks gestation. The condition forces clinicians into an impossible choice: deliver prematurely to save the mother, or risk escalating complications by prolonging pregnancy for fetal development. This therapeutic dilemma may now have a third option through targeted protein removal therapy. The pilot intervention used antibody-based apheresis to selectively extract soluble Fms-like tyrosine kinase 1 (sFlt-1), a placental protein that disrupts blood vessel function and drives preeclampsia's characteristic hypertension and organ dysfunction. The treatment demonstrated safety profiles comparable to standard plasma exchange while achieving modest blood pressure reductions and extending pregnancy duration in women with very preterm preeclampsia. This represents the first successful attempt to directly target the molecular mechanisms underlying preeclampsia rather than simply managing symptoms. The approach builds on decades of research identifying sFlt-1 as a central villain in preeclampsia pathophysiology. By binding and neutralizing beneficial proteins like VEGF and PlGF, excess sFlt-1 creates the endothelial dysfunction that characterizes the disease. However, this pilot study's modest effect sizes and small cohort demand cautious interpretation. The treatment appears more promising as a pregnancy extension strategy rather than a cure, potentially buying crucial weeks for fetal lung development. The intervention's complexity and cost will likely limit its application to severe early-onset cases where the maternal-fetal benefit ratio justifies the resource investment. Larger controlled trials will determine whether this molecular intervention can meaningfully alter preeclampsia outcomes.